|
|
|
The 3rd World Congress on
Controversies in Ophthalmology (COPHy)
Anterior Segment, Retina, Glaucoma
Istanbul, Turkey, March 22 - 25, 2012 |
|
 |
| Retina Section |
 |
|
|
|
Controversies Regarding Treatment of Non-Neovascular AMD
Room: Fuji 1
08:30-10:00
Chairpersons: S. Bressler, USA & A. Loewenstein, Israel
|
| Capsule: |
Rapid-fire discussion |
|
08:30-08:45
08:30-08:35
08:35-08:40
08:40-08:45
|
Dietary supplements such as those used in AREDs should not be recommended for people with geographic atrophy in each eye
Yes: P. Lanzetta, Italy
No: A. Loewenstein, Israel
Final disucssion with Panel: All Speakers
|
|
08:45-09:00
08:45-08:50
08:50-08:55
08:55-09:00 |
50 year-old children of parents in which both parents have advanced AMD (disciform scars) in both eyes and in which the children have no large drusen in both eyes should take dietary supplements
Yes: F. Bandello, Italy
No: S. Bressler, USA
Final disucssion with Panel
|
|
09:00-09:15
09:00-09:05
09:05-09:10
09:10-09:15 |
A diet rich in green leafy vegetables, or sunglasses, or both, should specifically be recommended to patients with large drusen in both eyes
Yes: B. Eldem, Turkey 
No: N. Bressler, USA
Final discussion with Panel
|
|
09:15-09:30
09:15-09:20
09:20-09:25
09:25-09:30 |
People aged 50 years of age and lder with no drusen in both eyes should have genetic screening for age-related macular degeneration
Yes: G. Soubrane, France
No: W. Mieler, USA
Final discussion with Panel
|
|
09:30-09:45
09:30-09:40
09:40-09:45 |
People with large drusen in both eyes should use an Amsler grid in each eye each day to monitor for the potential development of choroidal neovascularization
Yes & No: A. Loewenstein, Israel
Final discussion with Panel
|
|
09:45-10:00
09:45-09:50
09:50-09:55
09:55-10:00 |
People with large drusen in both eyes are at increased risk of progessing to choroidal neovascularization or geographic atrophy or both following cataract surgery
Yes: Y. Durlu, Turkey
No: J. Mones, Spain
Final discussion with Panel
|
|
Controversies Regarding Management of Macular Edema from Retinal Vein Occlusions
Room: Fuji 1
10:30-12:00
Chairpersons: F. Bandello, Italy & G. Coscas, France
|
| Capsule: |
Branch vein occlusion and macular edema - multiple optional treatments |
|
10:30-10:40
10:40-10:45
10:45-10:55
10:55-11:00
11:00-11:10
11:10-11:15
|
Ranibizumab or Bevacizumab monthly for 6 months
F. Bandello, Italy
Q&A from the audience, panel, chairpersons
Ranibizumab or Bevacizumab PRN
P. Lanzetta, Italy
Q&A from the audience, panel, chairpersons
Iluvien or Ozurdex
J. Mones, Spain
Q&A from the audience, panel, chairpersons |
| 11:15-12:00 |
Roundtable discussion
1) First-line therapy when finance is not an issue (a. Ranibizumab, b. Bevacizumab, c. VEGF-trap, fixed regimen or PRN for first 6 months, d. Ozurdex)
2) After 6 months (a. Ranibizumab PRN, Bevacizumab PRN, VEGF-trap PRN, b. Add grid laser, c. Add grid laser only if anti-VEGF does not work, d. Ozurdex)
Moderator: F. Bandello, Italy
Panel:
S. Arf, Turkey
G. Coscas, France
E. Cunha de Souza, Brazil
O. Gelisken, Turkey
J. Mones, Spain
|
|
Controversies on Imaging: Autofluorescence, OCT
Room: Fuji 1
14:00-15:30
Chairpersons: J. Cunha-Vaz, Portugal & U. Schmidt-Erfurth, Austria
|
| Capsule: |
Imaging in the present and future |
|
14:00-14:15
14:15-14:25
14:25-14:35
14:35-14:40
14:40-14:50
14:50-14:55
14:55-15:30
|
Autofluorescence: Pros and Cons
H. Scholl, USA
Q&A from the audience, panel, chairpersons
SD OCT leads to different outcomes than TD OCT
U. Schmidt-Erfurth, Austria
Q&A from the audience, panel, chairpersons
SD OCT does not lead to different outcomes than TD OCT
S. Bressler, USA
Q&A from the audience, panel, chairpersons
Discussion
Moderator: H. Scholl, USA
Panel:
S. Bressler, USA
J. Cunha-Vaz, Portugal
U. Schmidt-Erfurth, Austria
|
|
Tumor: Melanoma, Retinoblastoma, Lymphoma
Room: Fuji 1
17:00-18:30
Chairperson: B. Damato, UK
|
|
17:00-17:30
17:00-17:10
17:10-17:20
17:20-17:30
17:30-18:00
17:30-17:40
17:40-17:50
17:50-18:00
18:00-18:30
18:00-18:10
18:10-18:20
18:20-18:30 |
Debate I: Supra intra-arterial chemotherapy
Pro
H. Kiratli, Turkey
Con
K. Gunduz, Turkey
Discussion
Debate II: FNAB in uveal melanoma
Pro
B. Damato, UK
Con
H. Kiratli, Turkey
Discussion
Debate III: Treatment of vitreo-retinal lymphoma
In favor of intravitreal injections of methotrexate
B. Damato, UK
In favor of other modalities (systemic chemotherapy and irradiation)
K. Gunduz, Turkey
Discussion
|
|
Controversies in Treatment of Diabetic Macular Edema
Fuji 1
08:30-10:00
Chairpersons: B. Eldem, Turkey & G. Soubrane, France
|
| Capsule: |
Management of diabetic retinopathy in 2012 |
|
08:30-08:40
08:40-08:45
08:45-08:55
08:55-09:00
09:00-09:10
09:10-09:15
09:15-10:00 |
Focal Grid laser
G. Soubrane, France
Q&A from the audience, panel, chairpersons
Anti-VEGF therapy (e.g. DRCR Network Algorithm)
S. Bressler, USA
Q&A from the audience, panel, chairpersons
Other tretaments (e.g. combination therapy)
B. Eldem, Turkey
Q&A from the audience, panel, chairpersons
Roundtable discussion
Is it time to give up in DME: a. Fluorescein angiography, b. Diffuse vs. Focal terminology, c. Clinically significant macular edema terminology, d. Standard fundus photography, f. Wide-field fundus photography or fluorescein angiography, g. Contact lens biomicroscopy, h. Laser wavelength, i. Subthreshold laser, j. Suprathreshold laser, k. Short acting drugs, l. Long acting drugs?
Moderator: F. Bandello, Italy
Panel:
S. Arf, Turkey
S. Bressler, USA
E. Cunha de Souza, Brazil
J. Cunha-Vaz, Portugal
B. Eldem, Turkey
G. Soubrane, France
|
|
Surgery: Innovations
Room: Fuji 2
11:30-12:45
Chairpersons: W. Mieler, USA
|
| Capsule: |
New technologies and old problems |
| 11:30-12:00 |
Debate I: The best treatment for vitreoretinal interface disorders (Macular hole, vitreomacular traction, lameller holes) |
|
11:30-11:40
11:40-11:50
11:50-12:00
12:00-12:30
12:00-12:10
12:10-12:20 |
The natural history warrants observation
F. Boscia, Italy
Vitrectomy should be performed
S. Rizzo, Italy
Microplasmin
W. Mieler, USA
Debate II: The interface of Cataract surgery and Vitrectomy
Vitrectomy for retained lens fragments – indications, techniques and outcome
J. Nawrocki, Poland
Vitrectomy for dislocated IOLS – timing, techniques and refractive options |
|
12:20-12:30
|
A. Buchholz, Germany
The pros and cons for performing concurrent cataract surgery in patients |
|
12:30-12:45
|
undergoing posterior vitrectomy
S. Rizzo, Italy
Case presentations and Panel discussion
(2-3 cases)
Presenter: W. Mieler, USA
Panel:
F. Boscia, Italy
S. Kadayifcilar, Turkey
M. Karacorlu, Turkey
J. Nawrocki, Poland
S. Rizzo, Italy
G. Yilmaz, Turkey
|
|
Retina VII
Trauma: Orbital, Outer & Posterior Segment
Room: Fuji 1
16:15-17:30
Chairperson: W. Schrader, Germany
|
|
Capsule:
16:15-16:30
16:30-17:10
16:30-16:45
16:45-17:00
17:00-17:10
17:10-17:30 |
New technologies and old problems
Lecture: Combined anterior and posterior segment reconstruction
W. Schrader, Germany
Debate: Removal of IOFB - Timing and surgical approach
Pro: Immediate removal of the IOFB is critical
A. Nikolakopoulos, Greece
Con: Delayed removal is safe
W. Mieler, USA
Discussion
Case presentations and Panel discussion: Posterior segment trauma
Moderators: W. Schrader, Germany
Panel:
A. Barak, Israel
B. Eldem,Turkey
M. Karacorlu, Turkey
W. Mieler, USA
A. Nikolakopoulos, Greece
G. Sobaci, Turkey
|
|
|
|
|
WebStudio.co.il